Autopsy report · NCT05124691
Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Worms
Cause of deathFutility
“Primary Endpoint met”
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 2 months before it stopped.
- 1,001 participants enrolled.
- Results were posted on the registry 2 years 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- Barcelona Institute for Global Health
- Sponsor type
- University, hospital or other
- Conditions
- Helminthes; Infestation, Intestinal
- Interventions
- Albendazole and Ivermectin fixed dose coformulation; Albendazole
- Participants
- 1,001
- Sites
- 3
- Countries
- Ethiopia, Kenya, Mozambique
Trials that died the same way
- CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
“Primary Endpoint not met” - Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
“primary endpoint was not met” - Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
“Primary endpoint not achieved” - A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer
“Primary (safety) endpoint reached” - Utilization of AMSC to Enhance Rotator Cuff Repair - Safety and Efficacy
“Primary endpoint (safety) has been achieved”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.